Symbiosis Pharmaceutical Services News and Resources

Symbiosis Pharmaceutical Services has successfully completed an inspection by the US Food and Drug Administration (FDA) at its sterile manufacturing facilities in Scotland. The seven-day inspection, conducted in January 2025, resulted in zero Good Manufacturing Practice (GMP) observations, reinforcing the company’s

Symbiosis Pharmaceutical Services Ltd, a sterile biopharmaceutical contract manufacturing organisation (CMO), has purchased new premises in Stirling, Scotland. This acquisition will double the company’s footprint to 43,500 sq ft and is part of a £26 million investment aimed at increasing